Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of $4.08 billion. The enterprise value is $2.52 billion.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcyte has 129.00 million shares outstanding. The number of shares has increased by 23.64% in one year.
| Current Share Class | 129.00M |
| Shares Outstanding | 129.00M |
| Shares Change (YoY) | +23.64% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 0.68% |
| Owned by Institutions (%) | 105.02% |
| Float | 119.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.26 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.70, with a Debt / Equity ratio of 0.03.
| Current Ratio | 17.70 |
| Quick Ratio | 17.24 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.66% and return on invested capital (ROIC) is -15.00%.
| Return on Equity (ROE) | -19.66% |
| Return on Assets (ROA) | -14.53% |
| Return on Invested Capital (ROIC) | -15.00% |
| Return on Capital Employed (ROCE) | -19.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.23M |
| Employee Count | 414 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.54% in the last 52 weeks. The beta is 1.27, so Vaxcyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -51.54% |
| 50-Day Moving Average | 48.30 |
| 200-Day Moving Average | 82.35 |
| Relative Strength Index (RSI) | 37.91 |
| Average Volume (20 Days) | 2,144,629 |
Short Selling Information
The latest short interest is 12.04 million, so 9.34% of the outstanding shares have been sold short.
| Short Interest | 12.04M |
| Short Previous Month | 12.34M |
| Short % of Shares Out | 9.34% |
| Short % of Float | 10.08% |
| Short Ratio (days to cover) | 3.27 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -635.87M |
| Pretax Income | -497.19M |
| Net Income | -509.63M |
| EBITDA | -626.91M |
| EBIT | -635.87M |
| Earnings Per Share (EPS) | -$3.98 |
Full Income StatementBalance Sheet
The company has $1.67 billion in cash and $87.21 million in debt, giving a net cash position of $1.58 billion or $12.28 per share.
| Cash & Cash Equivalents | 1.67B |
| Total Debt | 87.21M |
| Net Cash | 1.58B |
| Net Cash Per Share | $12.28 |
| Equity (Book Value) | 3.20B |
| Book Value Per Share | 24.82 |
| Working Capital | 1.62B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$459.78 million and capital expenditures -$133.84 million, giving a free cash flow of -$593.62 million.
| Operating Cash Flow | -459.78M |
| Capital Expenditures | -133.84M |
| Free Cash Flow | -593.62M |
| FCF Per Share | -$4.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |